Beijing Science Sun Pharmaceutical Co Ltd Market Cap ($551.88 Million)
Market Cap & Net Worth: Beijing Science Sun Pharmaceutical Co Ltd (300485)
Beijing Science Sun Pharmaceutical Co Ltd market cap. Beijing Science Sun Pharmaceutical Co Ltd (SHE:300485) has a market capitalization of $551.88 Million (CN¥3.77 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #11425 globally and #3170 in its home market, demonstrating a 3.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Science Sun Pharmaceutical Co Ltd's stock price CN¥7.83 by its total outstanding shares 481666400 (481.67 Million). Also see Beijing Science Sun Pharmaceutical Co Lt (300485) cash conversion ratio for how efficiently the company converts equity into cash flow.
Beijing Science Sun Pharmaceutical Co Ltd Market Cap History (2015–2026)
Beijing Science Sun Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows change from $2.42 Billion to $551.88 Million (-8.02% CAGR). Check 300485 stock price and chart for real-time trading data and today's change.
Beijing Science Sun Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Science Sun Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Beijing Science Sun Pharmaceutical Co Lt equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.84x
Beijing Science Sun Pharmaceutical Co Ltd's market cap is 1.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
51.18x
Beijing Science Sun Pharmaceutical Co Ltd's market cap is 51.18 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.42 Billion | $616.24 Million | $258.41 Million | 2.30x | 5.49x |
| 2017 | $960.69 Million | $749.99 Million | $281.60 Million | 1.28x | 3.41x |
| 2018 | $660.12 Million | $1.43 Billion | $283.11 Million | 0.46x | 2.33x |
| 2019 | $613.30 Million | $1.19 Billion | $148.64 Million | 0.51x | 4.13x |
| 2020 | $1.01 Billion | $1.09 Billion | $154.90 Million | 0.92x | 6.51x |
| 2021 | $906.29 Million | $1.05 Billion | $402.27 Million | 0.86x | 2.25x |
| 2022 | $835.15 Million | $734.55 Million | $204.73 Million | 1.14x | 4.08x |
| 2023 | $744.12 Million | $476.57 Million | $102.92 Million | 1.56x | 7.23x |
| 2024 | $494.09 Million | $416.48 Million | -$68.85 Million | 1.19x | N/A |
| 2025 | $745.71 Million | $404.72 Million | $14.57 Million | 1.84x | 51.18x |
Competitor Companies of 300485 by Market Capitalization
Companies near Beijing Science Sun Pharmaceutical Co Ltd in the global market cap rankings as of November 5, 2026. Also see Beijing Science Sun Pharmaceutical Co Lt balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Beijing Science Sun Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Beijing Science Sun Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Beijing Science Sun Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Beijing Science Sun Pharmaceutical Co Ltd's market cap moved from $2.42 Billion to $ 551.88 Million, with a yearly change of -8.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥551.88 Million | -25.99% |
| 2025 | CN¥745.71 Million | +50.93% |
| 2024 | CN¥494.09 Million | -33.60% |
| 2023 | CN¥744.12 Million | -10.90% |
| 2022 | CN¥835.15 Million | -7.85% |
| 2021 | CN¥906.29 Million | -10.15% |
| 2020 | CN¥1.01 Billion | +64.47% |
| 2019 | CN¥613.30 Million | -7.09% |
| 2018 | CN¥660.12 Million | -31.29% |
| 2017 | CN¥960.69 Million | -32.24% |
| 2016 | CN¥1.42 Billion | -41.48% |
| 2015 | CN¥2.42 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Beijing Science Sun Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $551.88 Million USD |
| MoneyControl | $551.88 Million USD |
| MarketWatch | $551.88 Million USD |
| marketcap.company | $551.88 Million USD |
| Reuters | $551.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Science Sun Pharmaceutical Co Ltd
Beijing Science Sun Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of injections in China. The company offers products for cardiovascular, cerebrovascular, immunomodulation, and nervous systems, and other drugs. It is also involved in raw materials, solid oral preparations, and health products; extraction of traditional Chinese me… Read more